Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Supernus Pharmaceuticals Agrees To Buy Sage Therapeutics For $8.50/Share Plus One Contingent Value Right Worth Up To $3.50 Per Share In Cash, For Total Consideration Of $12/Share

Author: Benzinga Newsdesk | June 16, 2025 07:02am

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.
Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.
Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.
Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share.

Posted In: SAGE SUPN